AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02770989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vimecon Laser CAI percutaneous cardiac ablation
Description: The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
Study NCT01431781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stilamin+common daily treatment
Description: dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.~Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory.
Study NCT01431781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Common daily practice
Description: Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
Study NCT01053988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Study NCT01053988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF Inhalation Powder
Description: Inhaled Corticosteroid (ICS)
Study NCT01053988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 Inhalation Powder
Description: Long Acting Beta Agonist(LABA)
Study NCT01053988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02904733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth platform
Description: Use of a mHealth platform to inform and empower patient of hies/her own health
Study NCT02287428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concurrent Temozolomide (TMZ) = 75 mg/m2/day for 6 weeks, administered with XRT
Study NCT02287428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Adjuvant Temozolomide (TMZ) = 150 mg/m2/day on days 1-5 of each 28-day cycle for up to 6 adjuvant cycles
Study NCT01258803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Study NCT02287428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
Study NCT02388737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules or tablets
Study NCT01258803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Study NCT02388737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan Placebo
Description: Vonoprazan placebo-matching tablets
Study NCT02388737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Placebo
Description: Vonoprazan placebo-matching tablets
Study NCT01258803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI with spacer
Description: Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Study NCT01258803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI without spacer
Description: Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Study NCT01258803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate DPI
Description: Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
Study NCT02889861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCgp100
Description: Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
Study NCT03831282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD SET Neo SpO2
Description: All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
Study NCT00429546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching, Raising, and Communicating with Kids (TRACK)
Description: TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
Study NCT00429546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual includes standard care for HIV infected mothers.
Study NCT01451203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (SC)
Study NCT01451203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CZP
Description: SC
Study NCT01451203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX)
Description: oral
Study NCT01451203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate (MTX)
Description: oral
Study NCT04441619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed onset muscle soreness.
Description: Participants will perform a fatiguing exercise protocol for the upper extremity (biceps muscles)
Study NCT04981652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Milk
Description: Participants will consume twice daily whole milk beverages in addition to a standardized diet.
Study NCT04981652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skim Milk
Description: Participants will consume twice daily skim milk beverages in addition to a standardized diet.
Study NCT04981652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almond Beverage
Description: Participants will consume twice daily almond beverages in addition to a standardized diet.
Study NCT03948841 — intervention group
Intervention type: OTHER
Intervention: magnetic resonance imaging
Study NCT04322617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus the same Immune Checkpoint Inhibitors.
Description: Anlotinib, 8mg po qd, D1-D14 every 21days.
Study NCT04322617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus the new Immune Checkpoint Inhibitors.
Description: Anlotinib, 8mg po qd, D1-D14 every 21days.
Study NCT04322617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib, 8mg po qd, D1-D14 every 21days.
Study NCT00959595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream
Description: The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
Study NCT00959595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream
Description: 50g applied according to description of intervention
Study NCT00959595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EMLA cream
Description: 50g applied according to description of intervention
Study NCT01894932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive Group therapy
Description: In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams \& Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
Study NCT01894932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-physiological stress regulation group
Description: Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
Study NCT02000297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogenic bone graft
Description: Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
Study NCT02000297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Synthetic bone substitute (geneX®)
Description: Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
Study NCT01856582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+
Description: CD34+ cells are selected using the CliniMACS System; without preparative regimen
Study NCT03276897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)
Description: A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
Study NCT01379196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Tab. Azithromycin 500 mg PO three times weekly for 3 months
Study NCT03700567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low temperature contrast
Description: UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
Study NCT04362423 — intervention group
Intervention type: DEVICE
Intervention: fNIRS
Description: Near infrared spectroscopy (NIRS) is a non-invasive, portable, relatively inexpensive optical technology similar to pulse oximetry except that it measures total hemoglobin, oxy-hemoglobin, and deoxyhemoglobin in brain tissue (capillaries) rather than arteries.
Study NCT01546662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: E-RH-06
Description: Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
Study NCT01546662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1/ 2 capsules, twice daily for 12 weeks
Study NCT03203083 — intervention group
Intervention type: OTHER
Intervention: performance of the single leg squat task
Description: The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
Study NCT03009734 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ATx201 dermal formulations 2%
Description: Topical application of ATx201 dermal formulations 2%
Study NCT02388737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules
Study NCT03055000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-v
Description: AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
Study NCT03055000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-v + adjuvant
Description: ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
Study NCT03055000 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: WFI (0.5mL) on Day 0 and Day 21
Study NCT02423616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy individuals
Description: INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
Study NCT04408846 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lumbar fusion
Description: Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
Study NCT02409836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Dentifrice
Description: Marketed Dentifrice
Study NCT02409836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Flavored Dentifrice
Description: Hawaiian Punch Flavored
Study NCT02409836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Flavored Dentifrice
Description: Bubble Gum Flavored
Study NCT01538693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram oxalate
Description: 10 mg 4.5 hours prior to testing
Study NCT01538693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproheptadine
Description: 8mg 4.5 hours prior to testing
Study NCT01538693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: 4.5 hour prior to testing
Study NCT01538693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graded intensity exercise
Description: modified bruce protocol for peak oxygen consumption testing
Study NCT01538693 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Graded intensity exercise
Description: modified bruce protocol for peak oxygen consumption testing
Study NCT02259153 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changes in cholesterol metabolism
Study NCT02259153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lean red meat diet
Study NCT02259153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fat red meat diet
Study NCT04092166 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stationary Bike
Description: Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
Study NCT03250546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplant from a haplo-identical donor
Description: The transplant procedures will be similar in the 2 groups beside the origin of cells
Study NCT03250546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transplant from a non related donor
Description: The transplant procedures will be similar in the 2 groups beside the origin of cells
Study NCT01802957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training of health workers in Basic Obstetric Emergency Care
Description: Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
Study NCT01802957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hospital-health center networking system
Description: A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
Study NCT01802957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Post Basic Emergency Obstetric Training Mentorship
Description: At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
Study NCT01802957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Team-Based Supportive supervision
Description: Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
Study NCT01802957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Midwives exchange program
Description: Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
Study NCT01802957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Strengthening the referral network
Description: Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
Study NCT01802957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Facility Checklists
Description: Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
Study NCT01802957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emergency Drills
Description: Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
Study NCT03941535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
Study NCT01669291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bravelle and Menopur
Description: Bravelle and Menopur are used for controlled ovarian stimulation (COH)
Study NCT01669291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agonist
Description: Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
Study NCT03774069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Advisor Pro
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient
Study NCT03774069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical guided recommendation
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
Study NCT02764229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYC-30937-EC
Description: LYC-30937-EC 25 mg by mouth once daily
Study NCT00777504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usage oral angiogenesis inhibitor
Description: see under 'study arms'
Study NCT00777504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stop oral angiogenesis inhibitor
Description: see under 'study arms'